4Q Revenues: $12.6 billion (flat)
4Q Earnings: $9.4 billion (earnings were $2.7 billion 4Q2005)
FY Revenues: $48.4 billion (+2%)
FY Earnings: $19.3 billion (earnings were $8 billion FY2005)
Comments: Worldwide pharmaceutical revenues were $45.1 billion for the year, up 2%, and were flat at $11.7 billion for the quarter. U.S. revenues were $6.1 billion, down 3%, reflecting the loss of exclusivity of Zoloft in the U.S. in June 2006. Lipitor sales were flat at $3.3 billion in the quarter, and up 6% to $12.9 billion for the year. Nine products exceeded $1 billion in sales in 2006, with Detrol and Lyrica joining this list for the first time. Detrol sales for the year were $1.1 billion, up 11%. Lyrica sales were $1.2 billion, up from $291 million FY2005. R&D expenses were up 22% to $2.4 billion for the quarter and up 5% to $7.6 billion for the year. Earnings for the quarter and FY include significant gains from discontinued operations and the sale of the Consumer Healthcare Business. In the quarter, the company submitted filings with the FDA for Lyrica for Fibromyalgia and for Maraviroc.